Immune Checkpoint Inhibitors Market: Industry Analysis by Leading Players AstraZeneca PLC., Bristol-Myers Squibb Company, Eli Lilly and Company, Fortress Biotech, Inc., F. Hoffmann-La Roche Ltd, Immutep Limited, & Many Others

The global immune checkpoint inhibitors market was valued at $10,566 million in 2017, and is projected to reach $56,530 million by 2025, registering a CAGR of 20.1% from 2018 to 2025.

Surge in prevalence of cancer across geographies and increase in awareness of immune checkpoint inhibitors drive the growth of the global immune checkpoint inhibitors market. Furthermore, technological advancements in screening procedure for cancer, increased healthcare expenditures, increase in government initiatives to alleviate cancer, and rise in public awareness are expected to boost the growth of the market. However, high cost associated with research activities is projected to restrain the market growth.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/3723

Immune checkpoint inhibitor targets checkpoint proteins and assists the immune system to recognize and attack cancer cells. Immune checkpoint inhibitors are expected to exhibit significant market growth during the forecast period, due to upsurge in demand for ideal therapeutics for the treatment of cancer, favorable reimbursement policies provided by manufacturers & insurance providers in some countries, and surge in prevalence of cancer across the globe.

Based on type, the global immune checkpoint inhibitors market is categorized into CTLA-4 inhibitor, PD-1 inhibitor, PD-L1 inhibitor, and others. The PD-1 inhibitor segment was the major revenue contributor in 2017, and is anticipated to continue this trend during the forecast period, due to increase in adoption of PD-1 inhibitors such as pembrolizumab and nivolumab globally. However, PD-L1 inhibitor segment is projected to exhibit the fastest growth during the forecast period, owing to rise in use of durvalumab & avelumab and surge in R&D for combination studies of PD-L1 inhibitors for newer indications.

By application, the market is classified into lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others. The lung cancer segment presently dominates the market, and is expected to remain dominant during the forecast period, due to increase in use of immune check point inhibitors for the treatment of lung cancer and surge in prevalence of lung cancer globally. However, the bladder cancer segment is projected to show fastest growth during the forecast period, due to increase in incidence of bladder cancer.

Get More Information @ https://www.alliedmarketresearch.com/purchase-enquiry/3723

North America accounted for more than half of the global market share in 2017, and is expected to remain dominant throughout the forecast period. This is attributed to increase in demand for immune checkpoint inhibitors, high prevalence of cancer, rise in number of trained medical professionals, and supportive reimbursement policies in the healthcare system. However, Asia-Pacific is expected to experience the highest growth rate during the forecast period, majorly due to upsurge in prevalence of cancer coupled with increase in adoption of immune checkpoint inhibitors.

The key players profiled in this report include

• AstraZeneca PLC.,
• Bristol-Myers Squibb Company,
• Eli Lilly and Company (ARMO Biosciences.),
• Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.),
• F. Hoffmann-La Roche Ltd. (Genentech, Inc.),
• Immutep Limited,
• Merck & Co., Inc.,
• Merck KGaA (EMD Serono, Inc.),
• Novartis AG, and
• Pfizer Inc.

Table Of Content

Chapter: 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective

Chapter: 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Market share analysis
3.3. MARKET DYNAMICS
3.3.1. Drivers
3.3.1.1. Increase in incidence of cancer across the globe
3.3.1.2. Surge in global geriatric population
3.3.1.3. Supportive reimbursement policies for immune checkpoint inhibitors
3.3.1.4. Surge in healthcare expenditure worldwide
3.3.2. Restraint
3.3.2.1. Higher cost of immune checkpoint inhibitors
3.3.3. Opportunities
3.3.3.1. Increase in number of pipeline drugs
3.3.3.2. Growth opportunities in the emerging markets
3.3.4. Impact analyses
3.4. Clinical trials
3.5. Pipeline analyses

Access Full Summery @ https://www.alliedmarketresearch.com/press-release/immune-check-point-inhibitors-market.html

About us

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.